Suppr超能文献

肝门部胆管癌积极手术切除后结局改善:复发和生存的批判性分析。

Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival.

机构信息

Department of Surgery, Hepatobiliary and Surgical Oncology Unit, University of New South Wales, St. George Hospital, Level 3 Pitney Building, Short St., Kogarah, New South Wales 2217, Sydney, Australia.

出版信息

Am J Surg. 2011 Sep;202(3):310-20. doi: 10.1016/j.amjsurg.2010.08.041.

Abstract

BACKGROUND

Hilar cholangiocarcinoma (HC) is invariably fatal without surgical intervention. The primary aim of the current study was to report overall survival and recurrence-free survival outcomes after surgical resection of HC.

METHODS

Between December 1992 and December 2009, 85 patients were evaluated; of these, 42 patients underwent potentially curative surgery. These patients are the principal subjects of this study. Patients were assessed monthly for the first 3 months and then at 6-month intervals after treatment. Recurrence-free survival and overall survival were determined; 18 clinicopathologic and treatment-related factors associated with recurrence-free survival and overall survival were evaluated through univariate and multivariate analyses.

RESULTS

No patient was lost to follow-up evaluation. The median follow-up period was 20 months (range, 0-106 mo). The median recurrence-free survival and overall survival after resection was 15 and 28 months, respectively. The 5-year survival rate was 24%. Two factors were associated with overall survival: histologic grade (P = .002) and margin status (P = .033). Only histologic grade (P = .029) was associated with recurrence-free survival.

CONCLUSIONS

Surgical resection is an efficacious treatment for HC. Patient selection based on identified prognostic factors can improve treatment outcomes.

摘要

背景

肝门部胆管癌(HC)若不进行手术干预,其结果必然是致命的。本研究的主要目的是报告 HC 患者行手术切除后的总生存率和无复发生存率。

方法

1992 年 12 月至 2009 年 12 月期间,共评估了 85 例患者;其中,42 例患者接受了潜在的根治性手术。这些患者是本研究的主要研究对象。治疗后前 3 个月每月对患者进行评估,然后每 6 个月进行一次评估。确定无复发生存率和总生存率;通过单因素和多因素分析评估了 18 个与无复发生存率和总生存率相关的临床病理和治疗相关因素。

结果

无患者失访。中位随访时间为 20 个月(范围:0-106 个月)。切除后的中位无复发生存期和总生存期分别为 15 个月和 28 个月。5 年生存率为 24%。有两个因素与总生存率相关:组织学分级(P =.002)和切缘状态(P =.033)。只有组织学分级(P =.029)与无复发生存率相关。

结论

手术切除是 HC 有效的治疗方法。根据确定的预后因素进行患者选择可以改善治疗结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验